Traders sold shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on strength during trading on Thursday. $83.60 million flowed into the stock on the tick-up and $101.44 million flowed out of the stock on the tick-down, for a money net flow of $17.84 million out of the stock. Of all companies tracked, Regeneron Pharmaceuticals had the 0th highest net out-flow for the day. Regeneron Pharmaceuticals traded up $4.82 for the day and closed at $389.52

A number of brokerages have issued reports on REGN. Leerink Swann reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Saturday, April 30th. Piper Jaffray Cos. reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Sunday, May 8th. Wells Fargo & Co. reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 8th. Credit Suisse Group AG reaffirmed a “hold” rating and issued a $481.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, April 1st. Finally, Citigroup Inc. reaffirmed a “buy” rating and issued a $470.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 23rd. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and fourteen have issued a buy rating to the company. Regeneron Pharmaceuticals has an average rating of “Hold” and an average target price of $508.32.

The firm’s 50-day moving average price is $368.73 and its 200-day moving average price is $395.72. The company has a market capitalization of $40.62 billion and a price-to-earnings ratio of 61.76.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported $2.57 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.58 by $0.01. The company earned $1.20 billion during the quarter, compared to analyst estimates of $1.18 billion. Regeneron Pharmaceuticals’s quarterly revenue was up 38.0% compared to the same quarter last year. During the same quarter last year, the company posted $2.88 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals Inc. will post $10.78 earnings per share for the current fiscal year.

In other news, Director Arthur F. Ryan sold 1,000 shares of the business’s stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $396.64, for a total transaction of $396,640.00. Following the completion of the sale, the director now owns 40,500 shares in the company, valued at $16,063,920. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Sanofi bought 64,731 shares of the company’s stock in a transaction dated Tuesday, June 14th. The shares were purchased at an average price of $363.86 per share, with a total value of $23,553,021.66. The disclosure for this purchase can be found here.

Other institutional investors have recently modified their holdings of the company. Bank of Montreal Can raised its position in shares of Regeneron Pharmaceuticals by 4.8% in the fourth quarter. Bank of Montreal Can now owns 41,944 shares of the biopharmaceutical company’s stock valued at $22,770,000 after buying an additional 1,933 shares during the period. Ameritas Investment Partners Inc. raised its position in shares of Regeneron Pharmaceuticals by 1.0% in the fourth quarter. Ameritas Investment Partners Inc. now owns 3,170 shares of the biopharmaceutical company’s stock valued at $1,721,000 after buying an additional 32 shares during the period. Tredje AP fonden raised its position in shares of Regeneron Pharmaceuticals by 398.7% in the fourth quarter. Tredje AP fonden now owns 23,463 shares of the biopharmaceutical company’s stock valued at $12,737,000 after buying an additional 18,758 shares during the period. Sawtooth Asset Management Inc. raised its position in shares of Regeneron Pharmaceuticals by 6,115.5% in the fourth quarter. Sawtooth Asset Management Inc. now owns 3,605 shares of the biopharmaceutical company’s stock valued at $1,957,000 after buying an additional 3,547 shares during the period. Finally, Financial Counselors Inc. raised its position in shares of Regeneron Pharmaceuticals by 5.3% in the fourth quarter. Financial Counselors Inc. now owns 1,846 shares of the biopharmaceutical company’s stock valued at $1,002,000 after buying an additional 93 shares during the period.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.